Is EPRSQ or QYLD a better dividend investment in 2026?

EPRSQ currently yields 200000000.00% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: EPRSQ offers higher current income.

What is the dividend yield difference between EPRSQ and QYLD?

EPRSQ has a forward dividend yield of 200000000.00% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 199999988.08 percentage points.

Home › Compare › EPRSQ vs QYLD

EPRSQ vs QYLD: Dividend Comparison 2026

EPRSQ yields 200000000.00% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EPRSQ wins by $4.875657285131069e+59M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EPRSQ

● Live price

200000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.875657285131069e+59M

Annual income

$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00

Full EPRSQ calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — EPRSQ vs QYLD

📍 EPRSQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EPRSQ	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EPRSQ + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EPRSQ pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPRSQ

Annual income on $10K today (after 15% tax)

$17,000,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, EPRSQ beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPRSQ + QYLD for your $10,000?

EPRSQ: 50%QYLD: 50%

100% QYLD50/50100% EPRSQ

Portfolio after 10yr

$2.4378286425655345e+59M

Annual income

$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

100.00%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPRSQ buys

QYLD buys

No recent congressional trades found for EPRSQ or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEPRSQQYLD

Forward yield	200000000.00% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.875657285131069e+59M	$25.4K ✓
Annual income after 10y	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓	$5,659.31
Total dividends collected	$4.875656971401711e+59M	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: EPRSQ vs QYLD ($10,000, DRIP)

Year	EPRSQ Portfolio	EPRSQ Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$20,000,010,700	$20,000,000,000.00	$10,352	$1,192.36	+$20000.00M → EPRSQ
2	$37,383,218,970,104,910	$37,383,197,570,093,464.00	$10,830	$1,347.57	+$37383218970.09M → EPRSQ
3	$65,303,942,472,059,150,000,000	$65,303,902,472,014,860,000,000.00	$11,460	$1,539.07	+$65303942472059152.00M → EPRSQ
4	$106,615,009,060,306,890,000,000,000,000	$106,614,939,185,088,440,000,000,000,000.00	$12,275	$1,777.84	+$1.0661500906030689e+23M → EPRSQ
5	$162,672,273,967,082,950,000,000,000,000,000,000	$162,672,159,889,023,270,000,000,000,000,000,000.00	$13,323	$2,078.95	+$1.6267227396708296e+29M → EPRSQ
6	$231,966,340,306,755,300,000,000,000,000,000,000,000,000	$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00	$14,667	$2,463.34	+$2.319663403067553e+35M → EPRSQ
7	$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000	$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00	$16,396	$2,960.57	+$3.091381823051466e+41M → EPRSQ
8	$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000	$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00	$18,631	$3,612.97	+$3.850317772522584e+47M → EPRSQ
9	$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$21,548	$4,482.15	+$4.481844117993459e+53M → EPRSQ
10	$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$25,398	$5,659.31	+$4.875657285131069e+59M → EPRSQ

EPRSQ vs QYLD: Complete Analysis 2026

EPRSQ — Stock

EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

Full EPRSQ Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this EPRSQ vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPRSQ vs SCHD EPRSQ vs JEPI EPRSQ vs O EPRSQ vs KO EPRSQ vs MAIN EPRSQ vs XYLD EPRSQ vs JEPQ EPRSQ vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.